TRB Chemedica 
Welcome,         Profile    Billing    Logout  
 3 Products   3 Diseases  3 Products   5 Trials   215 News 
7 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ostenil (sodium hyaluronate) / TRB Chemedica
NCT03734315: Routine Application of Ostenil® in Patients with Gonarthrosis

Completed
N/A
115
Europe
Ostenil®
TRB Chemedica AG
Gonarthrosis
01/23
01/23
Vismed (sodium hyaluronate) / TRB Chemedica
IDROFLOG, NCT05724056: Idroflog® for Treatment of Dry Eye Disease

Not yet recruiting
N/A
130
Europe
Idroflog®, Study intervention, Sodium Hyaluronate 0.18% (Vismed®), Control intervention
Alfa Intes Industria Terapeutica Splendore s.r.l.
Dry Eye Disease
10/23
12/23
PROSIKA, NCT04701086: 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis

Completed
N/A
83
Europe
Cationorm Pro, Ocutears Pro+, Vismed
Santen SAS
Dry Eye Syndromes
04/25
04/25
ALHENA, NCT04685109: 3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis

Active, not recruiting
N/A
80
Europe
Alocross 0.2% Unit Dose, Vismed, HA 0.18% hypotonic solution
Santen SAS
Dry Eye Syndromes
09/26
09/26
NCT05965778: Comparison of the Performance and Safety of T2769 Versus Vismed® Multi in the Treatment of Moderate to Severe Dry Eye Syndrome

Recruiting
N/A
226
Europe
T2769, Vismed® Multi
Laboratoires Thea
Dry Eye
08/24
08/24
Talineuren (liposomal GM1) / Innomedica, TRB Chemedica
NCT06431971: Estimates of the Short-term Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease

Not yet recruiting
2
40
Europe
Talineuren, TLN, Liposomal GM1, Placebo, 0.9% NaCl
InnoMedica Schweiz AG
Parkinson Disease
11/25
12/25
NEON, NCT04976127: Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson's Disease-affected Patients

Active, not recruiting
1
22
Europe
Talineuren, liposomal GM1
InnoMedica Schweiz AG
Parkinson Disease
08/25
08/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ostenil (sodium hyaluronate) / TRB Chemedica
NCT03734315: Routine Application of Ostenil® in Patients with Gonarthrosis

Completed
N/A
115
Europe
Ostenil®
TRB Chemedica AG
Gonarthrosis
01/23
01/23
Vismed (sodium hyaluronate) / TRB Chemedica
IDROFLOG, NCT05724056: Idroflog® for Treatment of Dry Eye Disease

Not yet recruiting
N/A
130
Europe
Idroflog®, Study intervention, Sodium Hyaluronate 0.18% (Vismed®), Control intervention
Alfa Intes Industria Terapeutica Splendore s.r.l.
Dry Eye Disease
10/23
12/23
PROSIKA, NCT04701086: 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis

Completed
N/A
83
Europe
Cationorm Pro, Ocutears Pro+, Vismed
Santen SAS
Dry Eye Syndromes
04/25
04/25
ALHENA, NCT04685109: 3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis

Active, not recruiting
N/A
80
Europe
Alocross 0.2% Unit Dose, Vismed, HA 0.18% hypotonic solution
Santen SAS
Dry Eye Syndromes
09/26
09/26
NCT05965778: Comparison of the Performance and Safety of T2769 Versus Vismed® Multi in the Treatment of Moderate to Severe Dry Eye Syndrome

Recruiting
N/A
226
Europe
T2769, Vismed® Multi
Laboratoires Thea
Dry Eye
08/24
08/24
Talineuren (liposomal GM1) / Innomedica, TRB Chemedica
NCT06431971: Estimates of the Short-term Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease

Not yet recruiting
2
40
Europe
Talineuren, TLN, Liposomal GM1, Placebo, 0.9% NaCl
InnoMedica Schweiz AG
Parkinson Disease
11/25
12/25
NEON, NCT04976127: Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson's Disease-affected Patients

Active, not recruiting
1
22
Europe
Talineuren, liposomal GM1
InnoMedica Schweiz AG
Parkinson Disease
08/25
08/25

Download Options